Pharmacy benefit companies push big drug companies for price concessions through rebates. 99.6 percent of rebates get passed directly to Medicare Part D plans, and 91 percent to other health plan sponsors, like employers and unions, who use those savings
Court Ruling Finds that ERISA Preempts State PBM Law COURT REJECTS BID TO PREEMPT ERISA…In a unanimous decision, the U.S. Court of Appeals for the Tenth Circuit in PCMA v. Mulready court sustained PCMA’s challenge to four provisions in
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), discusses the root cause of high drug prices – big drug companies’ anti-competitive tactics used to keep more affordable prescription drugs from entering
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively leverage competition to reduce drug costs for health plan sponsors and patients. As biosimilar competition
©2024 PCMA. All Rights Reserved.
